Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 16/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.40 |
| ▸ | ABAT | P80404 | 1/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6706844 | 0.81 | ERN1 (0.42) | ERN1 | |
| SCHEMBL6704819 | 0.79 | GSK3B (0.53) | CRHBPCRHR2 | |
| SCHEMBL6704827 | 0.79 | GSK3B (0.53) | CRHBPCRHR2 | |
| SCHEMBL6618043 | 0.78 | TRIM24 (0.46) | ERN1ALDH5A1ABAT | |
| SCHEMBL6704722 | 0.71 | CA2 (0.43) | ERN1CRHBPCRHR2 | |
| SCHEMBL2553315 | 0.68 | TRIM24 (0.56) | ERN1CRHBPCRHR2ALDH5A1ABAT | |
| SCHEMBL4078626 | 0.68 | XDH (0.63) | ERN1XDHALDH5A1ABAT | |
| SCHEMBL9807400 | 0.67 | CYP1A2 (0.45) | — | |
| SCHEMBL13840638 | 0.67 | CA2 (0.47) | CRHBPCRHR2 | |
| SCHEMBL6623060 | 0.67 | TRIM24 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463718-A1 | 2-SUBSTITUTED THIAZOLIDINONE AND OXAZOLIDINONE DERIVATIVES FOR THE INHIBITION OF PHOSPHATASES AND THE TREATMENT OF CANCER | Incyte San Diego Incorporated (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040097566-A1 | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | INCYTE SAN DIEGO INCORPORATED | 2004-05-20 | — | — | US | disclosed |
| WO-2003050098-A1 | 2-SUBSTITUTED THIAZOLIDINONE AND OXAZOLIDINONE DERIVATIVES FOR THE INHIBITION OF PHOSPHATASES AND THE TREATMENT OF CANCER | INCYTE SAN DIEGO INCORPORATED (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097566-A1 | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | PTPA, PTPRC, PTPRCAP | ERN1 3033/4885CRHBP 3440/4885CRHR2 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.